SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-23-001387
Filing Date
2023-05-30
Accepted
2023-05-30 16:57:55
Documents
3

Document Format Files

Seq Description Document Type Size
1 THE SCHEDULE 13D sc13d13392meip_05302023.htm SC 13D 281984
2 GROUP AGREEMENT, DATED MAY 19, 2023 ex991to13d13392meip_05302023.pdf SC 13D 308170
3 ACQUISITION PROPOSAL, DATED MAY 23, 2023 ex992to13d13392meip_05302023.htm EX-99.2 11532
  Complete submission text file 0000921895-23-001387.txt   719917
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Subject) CIK: 0001262104 (see all company filings)

IRS No.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13D | Act: 34 | File No.: 005-79594 | Film No.: 23977407
SIC: 2834 Pharmaceutical Preparations

Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

IRS No.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SC 13D